ADMA Biologics reports record FY2025 revenue $510M (+20%), Adj. EBITDA $231M (+40%); CFO transition to Kohler

ADMA BIOLOGICS, INC.

2025-FY EPS reported $0.60 revenue$510,173,000

FY2025 total revenue $510.2M (+20% YoY); ASCENIV revenue $363M (+51% YoY). Gross margin 57.4% vs 51.5%.
GAAP net income $146.9M (FY2024: $197.7M incl. $84.3M tax benefit). Adjusted net income $160.8M (+35% YoY). Adjusted EBITDA $231M (+40%).
FY2026 guidance: revenue >$635M, Adj. net income >$255M, Adj. EBITDA >$360M. Targeting >$1.1B revenue by FY2029.
CFO Brad Tade retiring effective Feb 25, 2026; succeeded by Terry Kohler (ex-CFO of OptiNose, Verrica). Kohler will become CFO/Treasurer Feb 26.
Q4 2025: revenue $139.2M (+18% YoY); GAAP net income $49.4M; Adj. EBITDA $73.6M (+52% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.